Boston Red Sox Notes: Drew Pomeranz Received Stem Cell Shot Injection After Playoff Run – Scout
Scout |
Boston Red Sox Notes: Drew Pomeranz Received Stem Cell Shot Injection After Playoff Run
Scout The 2016 All-Star explained that after the Red Sox were defeated by the Cleveland Indians and eliminated from the playoffs, he received a stem cell shot in the elbow/forearm area. Pomeranz noted, that “we just looked at ways to speed up the process of … |
Mesothelioma Research News |
Mayo Clinic Expert Stands By Checkpoint Immunotherapy’s Potential for Treating Pleural Mesothelioma
Mesothelioma Research News Many scientists may have lost their initial high hopes for checkpoint immunities in treating malignant pleural mesothelioma (MPM), but Aaron S. Mansfield, MD, at the Mayo Clinic remains convinced immunotherapy will replace current second-line treatment … |
Mesothelioma Research News |
Mayo Clinic Expert Stands By Checkpoint Immunotherapy’s Potential for Treating Pleural Mesothelioma
Mesothelioma Research News Many scientists may have lost their initial high hopes for checkpoint immunities in treating malignant pleural mesothelioma (MPM), but Aaron S. Mansfield, MD, at the Mayo Clinic remains convinced immunotherapy will replace current second-line treatment … |
FierceBiotech |
Abeona says it will start Sanfilippo B gene therapy trial in Q2
FierceBiotech Abeona Therapeutics announced it is just weeks away from enrolling the first patients in a trial of its gene therapy for the lysosomal storage disease Sanfilippo B. The new comes as the gene therapy candidate—called ABO-101—has just been awarded … |
TrendinTech |
CRISPR and Seven Big Science Stories We Might See in the Future
TrendinTech CRISPR is big news, and it will continue to be big news throughout 2017. Genetic engineering and gene editing technology make it possible to cure some diseases and illnesses by simply altering the person’s DNA. With the help of CRISPR/Cas9 technology … |
|
The New Era of First-Line Immunotherapy for Advanced NSCLC
Medscape As valuable as it has been to get new approvals for patients with previously treated advanced non–small cell lung cancer (NSCLC), as described recently, the stakes are even higher when a new therapy is approved in the first-line setting. With the … |